KOL | Harry J G M C CrijnsDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands | Cardiovascular Research ... |
KOL Resume for Harry J G M C Crijns
| Year | |
|---|---|
| 2022 | Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands |
| 2021 | Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Netherlands Preventive and Clinical Investigation Center, Paris, France |
| 2020 |
|
| 2019 | From the Departments of Cardiology (N.A.H.A.P., E.A.M.P.D., J.G.L.M.L., H.J.G.M.C.) and Clinical Epidemiology and Medical Technology Assessment (B.A.B.E.), the Cardiovascular Research Institute Maastricht (N.A.H.A.P., E.A.M.P.D., J.G.L.M.L., H.J.G.M.C.), Maastricht University Medical Center, Maastricht, VieCuri Medical Center Noord-Limburg, Venlo (J.G.M.), Zuyderland Medical Center, Heerlen (T.L.), Elisabeth-TweeSteden Hospital, Tilburg (J.W.), Diakonessen Hospital, Utrecht (J.J.J.B.), University of Groningen, Groningen (M.R., I.C.V.G.), VU University Medical Center Amsterdam (O.K.) and Academic Medical Center (J.G.P.T), Amsterdam, Medical Spectrum Twente, Enschede (J.M.V.O.), Amphia Hospital, Breda (M.A.), Antonius Hospital, Sneek (A.O.), Alrijne Hospital, Leiderdorp (C.J.K.), St. Antonius Hospital, Nieuwegein (V.F.V.D.), Haga Teaching Hospital, The Hague (H.R.), St. Franciscus Gasthuis, Rotterdam (A.L.), and Catharina Hospital, Eindhoven (L.R.D) - all in the Netherlands. Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands |
Harry J G M C Crijns: Influence Statistics
| Concept | World rank |
|---|---|
| race trials | #1 |
| lenient rate control | #1 |
| “tele | #1 |
| atrial fibrillation 95ci | #1 |
| lge biventricular lge | #1 |
| paroxysms atrial fibrillation | #1 |
| holter monitoring ack | #1 |
| serial drug treatment | #1 |
| european telecheckaf project | #1 |
| medication stability | #1 |
| epicardial validation | #1 |
| netherlands vhd | #1 |
| predictive performance auc | #1 |
| cryoballoon ablation pv | #1 |
| usualcare | #1 |
| angiography strategy | #1 |
| ablation clinics | #1 |
| afl 4 patients | #1 |
| patients idiopathic paroxysmal | #1 |
| atrial size cardioversion | #1 |
| fibrillation therapy | #1 |
| remote mhealth infrastructure | #1 |
| cryothermal laser | #1 |
| interpretation interval | #1 |
| rhythm cardioversion | #1 |
| nurseled | #1 |
| cardiac disease improvement | #1 |
| 95ci aortic incompetence | #1 |
| mapd almokalant | #1 |
| remote rhythm monitoring | #1 |
| ventricular proarrhythmic | #1 |
| hp pwd | #1 |
| 120 nicd | #1 |
| metaanalysis echocardiographic predictors | #1 |
| maintain sinus | #1 |
| vveff delay | #1 |
| aorta calcification dac | #1 |
| verapamil progression | #1 |
| ack detection | #1 |
| scale knowledge levels | #1 |
| sinus rhythm patients | #1 |
| crt adv | #1 |
| patients34 | #1 |
| nexfin vtiao measurements | #1 |
| adherence stability | #1 |
| apelin auc | #1 |
| undecided issues | #1 |
| afl emphasis | #1 |
| cardioversion status | #1 |
| 40 minutes infusion | #1 |
Open the FULL List in Excel | |
Prominent publications by Harry J G M C Crijns
OBJECTIVES: This study aimed to determine the diagnostic accuracy of the 3 most commonly used noninvasive myocardial perfusion imaging modalities, single-photon emission computed tomography (SPECT), cardiac magnetic resonance (CMR), and positron emission tomography (PET) perfusion imaging for the diagnosis of obstructive coronary artery disease (CAD). Additionally, the effect of test and study characteristics was explored.
BACKGROUND: Accurate detection of obstructive CAD is important ...
| Known for Perfusion Imaging | Computed Tomography | Cardiac Magnetic Resonance | Cmr Pet | Positron Emission |
BACKGROUND: Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the ...
| Known for Cardiovascular Hospitalization | Dronedarone Patients | Stroke Atrial Fibrillation | Atrial Flutter | Antithrombotic Therapy |
OBJECTIVES: The purpose of this study was to assess whether management of heart failure (HF) guided by an individualized N-terminal pro-B-type natriuretic peptide (NT-proBNP) target would lead to improved outcome compared with HF management guided by clinical assessment alone.
BACKGROUND: Natriuretic peptides may be attractive biomarkers to guide management of heart failure (HF) and help select patients in need of more aggressive therapy. The PRIMA (Can PRo-brain-natriuretic peptide ...
| Known for Chronic Heart | Peptide Guided | Hf Management | Primary Point | Admission Discharge |
OBJECTIVE: The reporting of depressive symptoms following myocardial infarction may be confounded by complaints originating from the myocardial infarction. Therefore, it is difficult to estimate the effects of post-myocardial infarction depression and its treatment on cardiovascular prognosis. The authors' goal was to study the relationship between depressive symptom dimensions following myocardial infarction and both somatic health status and prospective cardiovascular ...
| Known for Cardiovascular Prognosis | Myocardial Infarction | Somatic Health | Symptom Dimensions | Cardiac Events |
Changes in left and right atrial size after cardioversion of atrial fibrillation: Role of mitral valve disease
[ PUBLICATION ]
OBJECTIVES: The aim of this study was to examine the effect of cardioversion on left and right atrial volume in patients with chronic atrial fibrillation and to determine the influence of mitral valve disease on atrial size.
BACKGROUND: Atrial enlargement is a common finding in atrial fibrillation and has been associated with an increased risk for embolic stroke. In addition, atrial enlargement may hamper long-term maintenance of sinus rhythm after cardioversion.
METHODS: Forty-one ...
| Known for Mitral Valve Disease | Atrial Size | Sinus Rhythm | 6 Months | Fibrillation Patients |
BACKGROUND: The EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot) provides systematic collection of contemporary data regarding the management and treatment of 3119 subjects with AF from 9 member European Society of Cardiology (ESC) countries. In this analysis, we report the development of symptoms, use of antithrombotic therapy and rate vs. rhythm strategies, as well as determinants of mortality and/or stroke/transient ischaemic attack ...
| Known for Year Follow | Fibrillation Patients | Pilot Registry | Heart Failure | Mortality Age |
BACKGROUND: The combination of left bundle branch block (LBBB) morphology and QRS duration is currently used to select patients for cardiac resynchronization therapy (CRT). These parameters, however, have limitations. This study evaluates the value of QRS area compared with that of QRS duration and morphology in the association with clinical and echocardiographic outcomes in a large cohort of CRT patients.
METHODS: A retrospective multicentre study was conducted in 1492 CRT patients. ...
| Known for Qrs Area | Cardiac Resynchronization | Patients Crt | Bundle Branch | Echocardiographic Response |
BACKGROUND: Vitamin K antagonists, the current standard treatment for prophylaxis against stroke and systemic embolism in patients with atrial fibrillation, require regular monitoring and dose adjustment; an unmonitored, fixed-dose anticoagulant regimen would be preferable. The aim of this randomised, open-label non-inferiority trial was to compare the efficacy and safety of idraparinux with vitamin K antagonists.
METHODS: Patients with atrial fibrillation at risk for thromboembolism ...
| Known for Atrial Fibrillation | Vitamin Antagonists | Thromboembolism Patients | Systemic Embolism | Treatment Idraparinux |
OBJECTIVES: We studied the influence of rate control or rhythm control in patients with persistent atrial fibrillation (AF) on quality of life (QoL).
BACKGROUND: Atrial fibrillation may cause symptoms like fatigue and dyspnea. This can impair QoL. Treatment of AF with either rate or rhythm control may influence QoL.
METHOD: Quality of life was assessed in patients included in the Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study (rate vs. rhythm ...
| Known for Rhythm Control | Life Qol | Persistent Atrial | Baseline Study | Electrical Cardioversion |
OBJECTIVES: The purpose of this study was to evaluate left ventricular function and atrial and ventricular diameters in patients with persistent atrial fibrillation (AF) treated with rate or rhythm control.
BACKGROUND: Restoration of sinus rhythm in patients with persistent AF may improve left ventricular function and reduce atrial dimensions. Adequate rate control in AF may preserve ventricular function.
METHODS: In 335 patients included in the RAte Control versus Electrical ...
| Known for Ventricular Function | Rate Control | Persistent Atrial Fibrillation | Electrical Cardioversion | Sinus Rhythm Patients |
A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: Maintenance of sinus rhythm is the main therapeutic goal in patients with atrial fibrillation. However, recurrences of atrial fibrillation and side effects of antiarrhythmic drugs offset the benefits of sinus rhythm. We hypothesized that ventricular rate control is not inferior to the maintenance of sinus rhythm for the treatment of atrial fibrillation.
METHODS: We randomly assigned 522 patients who had persistent atrial fibrillation after a previous electrical cardioversion ...
| Known for Rhythm Control | Atrial Fibrillation | Primary Point | Patients Rate | Death Cardiovascular |
BACKGROUND: Despite improvements in the management of atrial fibrillation, patients with this condition remain at increased risk for cardiovascular complications. It is unclear whether early rhythm-control therapy can reduce this risk.
METHODS: In this international, investigator-initiated, parallel-group, open, blinded-outcome-assessment trial, we randomly assigned patients who had early atrial fibrillation (diagnosed ≤1 year before enrollment) and cardiovascular conditions to receive ...
| Known for Early Rhythm | Atrial Fibrillation | Control Therapy | Patients Usual | Ventricular Function |
BACKGROUND: Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation.
METHODS: We conducted a multicenter trial to evaluate the use of dronedarone in 4628 patients with atrial fibrillation who had additional risk factors for death. Patients were randomly assigned to receive dronedarone, 400 mg twice a day, or placebo. The primary outcome was the first hospitalization due to cardiovascular events or death. Secondary outcomes ...
| Known for Cardiovascular Events | Atrial Fibrillation | Death Patients | Hazard Ratio | Study Drug |
AIMS: Guideline-adherent therapy for stroke prevention in atrial fibrillation has been associated with better outcomes, in terms of thromboembolism (TE) and bleeding.
METHODS AND RESULTS: In this report from the EuroObservational Research Programme-Atrial Fibrillation (EORP-AF) Pilot General Registry, we describe the associated baseline features of 'high risk' AF patients in relation to guideline-adherent antithrombotic treatment, i.e. whether they were adherent, over-treated, or ...
| Known for Atrial Fibrillation | Antithrombotic Treatment | Oral Aged Aged | Esc Guidelines | Guideline Adherent |
Key People For Atrial Fibrillation
Harry J G M C:Expert Impact
Concepts for whichHarry J G M Chas direct influence:Atrial fibrillation, Heart failure, Sinus rhythm, Rate control, Rhythm control, Patients atrial fibrillation, Myocardial infarction, Electrical cardioversion.
Harry J G M C:KOL impact
Concepts related to the work of other authors for whichfor which Harry J G M C has influence:Atrial fibrillation, Heart failure, Catheter ablation, Sinus rhythm, Ischemic stroke, Myocardial infarction, Oral anticoagulants.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |